Changeflow GovPing Healthcare & Life Sciences Patent Application: Bifidobacterium longum for ...
Routine Notice Added Draft

Patent Application: Bifidobacterium longum for Infant Infection Prevention

Email

Summary

The USPTO has published a patent application (US20260083785A1) detailing the use of Bifidobacterium longum transitional microorganisms to prevent or reduce the risk of infection in infants and young children. The application was filed on September 27, 2023.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO, specifically application US20260083785A1, filed on September 27, 2023. It describes the use of a Bifidobacterium longum transitional microorganism for preventing or reducing the risk of infection in infants and young children.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in therapeutic applications for probiotics in pediatric health. Companies involved in the development or manufacturing of probiotics, infant formula, or pediatric therapeutics should monitor the progress of this and similar patent applications as they may impact intellectual property landscapes and future product innovation in the sector.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

USES OF BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISM

Application US20260083785A1 Kind: A1 Mar 26, 2026

Inventors

Cheong Kwet Choy (William) KWONG CHUNG, Jean-Baptiste CAVIN, Claire Laurence Lucie Marie BOULANGE, Eleonora CIARLO

Abstract

The present invention relates to a Bifidobacterium longum transitional microorganism for use in preventing and/or reducing the risk of an infection in an infant or young child.

CPC Classifications

A61K 35/745 A61K 31/702 A61P 31/12 A61K 2035/115

Filing Date

2023-09-27

Application No.

19112879

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083785A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Probiotic Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Product Development
Compliance frameworks
GxP
Topics
Public Health Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!